These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Changes in hemostatic parameters after oral hormone therapy in postmenopausal women. Borowiecka M, Polac I, Nowak P, Radwan P, Ponczek MB, Wachowicz B. J Womens Health (Larchmt); 2010 Dec; 19(12):2267-70. PubMed ID: 21054215 [Abstract] [Full Text] [Related]
4. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration? Brosnan JF, Sheppard BL, Norris LA. Thromb Haemost; 2007 Apr; 97(4):558-65. PubMed ID: 17393018 [Abstract] [Full Text] [Related]
5. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Zegura B, Guzic-Salobir B, Sebestjen M, Keber I. Menopause; 2006 Apr; 13(4):643-50. PubMed ID: 16837886 [Abstract] [Full Text] [Related]
6. Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone. Norris LA, Brosnan J, Bonnar J, Conard J, Kluft C, Hellgren M. Thromb Haemost; 2008 Aug; 100(2):253-60. PubMed ID: 18690345 [Abstract] [Full Text] [Related]
8. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. Roach RE, Lijfering WM, Helmerhorst FM, Cannegieter SC, Rosendaal FR, van Hylckama Vlieg A. J Thromb Haemost; 2013 Jan; 11(1):124-31. PubMed ID: 23136837 [Abstract] [Full Text] [Related]
14. Increased thrombin generation among postmenopausal women using hormone therapy: importance of the route of estrogen administration and progestogens. Scarabin PY, Hemker HC, Clément C, Soisson V, Alhenc-Gelas M. Menopause; 2011 Aug; 18(8):873-9. PubMed ID: 21487317 [Abstract] [Full Text] [Related]
15. Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone. Hellgren M, Conard J, Norris L, Kluft C. Maturitas; 2009 Mar 20; 62(3):287-93. PubMed ID: 19268506 [Abstract] [Full Text] [Related]
16. Hormone therapy and hemostasis among postmenopausal women: a review. Canonico M. Menopause; 2014 Jul 20; 21(7):753-62. PubMed ID: 24937030 [Abstract] [Full Text] [Related]
17. Hormone therapy and venous thromboembolism among postmenopausal women. Scarabin PY. Front Horm Res; 2014 Jul 20; 43():21-32. PubMed ID: 24943295 [Abstract] [Full Text] [Related]
18. Hormone therapy and risk of venous thromboembolism among postmenopausal women. Canonico M. Maturitas; 2015 Nov 20; 82(3):304-7. PubMed ID: 26276103 [Abstract] [Full Text] [Related]
19. Differential effect of the ultra-low dose and standard estrogen plus dydrogesterone therapy on thrombin generation and fibrinolysis in postmenopausal women. Piróg M, Jach R, Kacalska-Janssen O. Acta Obstet Gynecol Scand; 2017 Dec 20; 96(12):1438-1445. PubMed ID: 28981954 [Abstract] [Full Text] [Related]
20. Is there a place for postmenopausal hormone therapy use in women with lupus? Gompel A, Piette JC. Panminerva Med; 2008 Sep 20; 50(3):247-54. PubMed ID: 18927529 [Abstract] [Full Text] [Related] Page: [Next] [New Search]